Natera (NTRA) Form 4: Officer Sells 3,000 Shares at ~$133 Avg Price

Q: What trades did Natera officer Solomon Moshkevich report on Form 4 (NTRA)?

On 08/01/2025 Moshkevich reported three sales: 1,574 shares at a weighted-average of $132.4528 , 1,326 shares at $133.3097 , and 100 shares at $134.08 .

Q: When was the Form 4 signed and filed?

The Form 4 was signed by an attorney-in-fact on 08/05/2025 .

[Form 4] Natera, Inc. Insider Trading Activity

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Insider Form 4 filing 鈥� Natera, Inc. (NTRA)

On 08/01/2025, Solomon Moshkevich (President, Clinical Diagnostics; officer) reported three sales of Natera common stock effected pursuant to a Rule 10b5-1 trading plan adopted on 11/26/2024. The reported dispositions were 1,574 shares at a weighted-average price of $132.4528 (range $131.9350鈥�$132.78), 1,326 shares at $133.3097 (range $132.96鈥�$133.80), and 100 shares at $134.08.

Post-transaction beneficial ownership: reported as 124,485; 123,159; and 123,059 shares respectively. The Form was signed by an attorney-in-fact on 08/05/2025.

Positive

Sales executed under a Rule 10b5-1 trading plan adopted 11/26/2024, which can reduce signalling concerns
Weighted-average prices and price ranges disclosed for the sales, enhancing transparency
Form 4 filed and signed by attorney-in-fact on 08/05/2025, meeting reporting formalities

Negative

Insider disposed of 3,000 shares (1,574; 1,326; 100) on 08/01/2025
Post-transaction beneficial ownership decreased to reported levels of 124,485; 123,159; and 123,059 shares

Insights

TL;DR: Officer sold 3,000 NTRA shares under a pre-established 10b5-1 plan; disclosed weighted-average prices and post-sale holdings.

The filing documents routine insider dispositions totaling 3,000 shares executed on 08/01/2025 under a Rule 10b5-1 plan adopted 11/26/2024. Weighted-average prices and price ranges are provided, improving transparency on execution pricing. Given the disclosure of a pre-established trading plan and relatively modest absolute volume, the transactions are unlikely to materially affect valuation absent other company developments.

Impact assessment: Not impactful for most investors; procedural disclosure reduces signaling risk.

TL;DR: Use of a Rule 10b5-1 plan indicates pre-planned sales; disclosure complies with Section 16 filing requirements.

The Form 4 confirms compliance with Section 16 reporting and states the sales were made pursuant to a 10b5-1 plan (adopted 11/26/2024). The filing lists precise share counts, weighted-average prices, and post-transaction beneficial ownership, and is signed via attorney-in-fact on 08/05/2025. These elements align with standard insider-trading governance practices and reduce the likelihood that the trades reflect contemporaneous material nonpublic information.

Impact assessment: Not impactful; governance adherence is routine and mitigates regulatory risk.

08/05/2025 - 09:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moshkevich Solomon

(Last)

(First)

(Middle)

C/O NATERA, INC.

13011 MCCALLEN PASS BUILDING A SUITE 100

(Street)

AUSTIN

78753

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Natera, Inc. [ NTRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT, CLINICALDIAGNOSTICS

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/01/2025		S		1,574⁽¹⁾	D	$132.4528⁽²⁾	124,485	D
Common Stock	08/01/2025		S		1,326⁽¹⁾	D	$133.3097⁽³⁾	123,159	D
Common Stock	08/01/2025		S		100⁽¹⁾	D	$134.08	123,059	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.9350 to $132.78 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.96 to $133.80 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Vincent Fontanilla, Attorney-in-Fact	08/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What trades did Natera officer Solomon Moshkevich report on Form 4 (NTRA)?

On 08/01/2025 Moshkevich reported three sales: 1,574 shares at a weighted-average of $132.4528, 1,326 shares at $133.3097, and 100 shares at $134.08.

Were the sales part of a pre-established trading plan for NTRA?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on 11/26/2024.

How many shares were owned after the reported transactions?

The filing reports post-transaction beneficial ownership of 124,485, 123,159, and 123,059 shares respectively.

When was the Form 4 signed and filed?

The Form 4 was signed by an attorney-in-fact on 08/05/2025.

Do the disclosures include execution price ranges?

Yes. Footnotes disclose price ranges for the weighted-average prices: $131.9350鈥�$132.78 and $132.96鈥�$133.80 for the respective blocks.

AG真人官方

[Form 4] Natera, Inc. Insider Trading Activity

Insights

FAQ

What trades did Natera officer Solomon Moshkevich report on Form 4 (NTRA)?

Were the sales part of a pre-established trading plan for NTRA?

How many shares were owned after the reported transactions?

When was the Form 4 signed and filed?

Do the disclosures include execution price ranges?

NASDAQ:NTRA

NTRA Rankings

NTRA Latest News

NTRA Latest SEC Filings

NTRA Stock Data

AG真人官方

Trending News

[Form 4] Natera, Inc. Insider Trading Activity

Insights

Financial Analyst neutral

Corporate Governance Expert neutral

FAQ

What trades did Natera officer Solomon Moshkevich report on Form 4 (NTRA)?

Were the sales part of a pre-established trading plan for NTRA?

How many shares were owned after the reported transactions?

When was the Form 4 signed and filed?

Do the disclosures include execution price ranges?

NASDAQ:NTRA

NTRA Rankings

NTRA Latest News

NTRA Latest SEC Filings

NTRA Stock Data